A German pharmaceutical company specializing in the importation and wholesale of medical cannabis is facing scrutiny following claims that the company is distributing different cannabis cultivars under the same marketing authorization numbers and drug names.
Remexian distributing different strains from different cultivars under the same name matches anecdotes of fluctuating quality of their products.